List of Excipients in Branded Drug SULFAMYLON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rising Pharma Holdings Inc	SULFAMYLON	mafenide acetate	16571-723	CETYL ALCOHOL
Rising Pharma Holdings Inc	SULFAMYLON	mafenide acetate	16571-723	EDETATE DISODIUM
Rising Pharma Holdings Inc	SULFAMYLON	mafenide acetate	16571-723	GLYCERIN
Rising Pharma Holdings Inc	SULFAMYLON	mafenide acetate	16571-723	METHYLPARABEN

Sulfamylon Excipient Strategy and Commercial Opportunities for Mafenide Acetate

Last updated: August 8, 2026

Sulfamylon is a legacy topical burn antimicrobial containing mafenide acetate. Its commercial opportunity is not primarily molecule ownership. It is formulation performance: improving residence time, application efficiency, wound compatibility, storage, dressing integration, and usability while preserving the established mafenide acetate exposure profile.

The strongest product concepts are ready-to-use hydrogels, sprayable or foam formulations, dressing-impregnated systems, and lower-irritancy creams. A new product would likely rely on formulation, manufacturing, device, or method-of-use claims rather than composition-of-matter protection.

What is Sulfamylon and how is mafenide acetate used?

Sulfamylon cream contains 8.5% mafenide acetate, equivalent to 5% mafenide, for topical treatment of second- and third-degree burns. The product is applied directly to the burn wound, commonly at a thickness sufficient to maintain coverage, and reapplied as needed when the cream is removed or absorbed during wound care [1].

Mafenide is a sulfonamide antimicrobial. Unlike many topical antibiotics, it has activity against a broad range of gram-positive and gram-negative organisms, including organisms that can complicate burn wounds. The FDA label identifies use in burn wound management and reports systemic absorption through burned skin, with higher absorption associated with larger treated areas and prolonged exposure [1].

Core product attributes

Attribute	Sulfamylon profile
Active ingredient	Mafenide acetate
Labeled strength	8.5% mafenide acetate, equivalent to 5% mafenide
Dosage form	Topical cream
Primary use	Second- and third-degree burns
Route	Topical
Regulatory application	NDA 016078
Main clinical setting	Burn centers, hospitals, trauma care
Key formulation issue	Maintaining wound coverage while limiting pain, irritation, mess, and reapplication burden
Key safety issue	Systemic absorption and metabolic acidosis risk in extensive burns
Patent position	Legacy product with limited apparent Orange Book patent protection; value is concentrated in product and regulatory execution

What excipients are used in Sulfamylon cream?

The marketed cream uses a hydrophilic cream base containing fatty alcohols and a nonionic surfactant. FDA labeling identifies cetyl alcohol, stearyl alcohol, polysorbate 60, and purified water among the inactive ingredients [1,2].

These excipients perform several functions:

• Cetyl alcohol and stearyl alcohol provide structure, viscosity, emollience, and spreadability.
• Polysorbate 60 supports emulsification and dispersion of the active ingredient.
• Water provides the continuous hydrophilic phase.
• The cream base permits application to irregular, exudative wound surfaces.

The excipient system is commercially useful because it is familiar, relatively simple, and compatible with a hospital-applied topical product. It also leaves room for differentiation. The current base can be improved in several areas: delivery from the container, wash-off resistance, wound-bed residence, tactile properties, compatibility with dressings, and patient or caregiver comfort.

What formulation constraints apply to mafenide acetate?

Mafenide acetate formulation development is constrained by the wound environment rather than by ordinary dermatology requirements. Burn wounds may have high exudate, damaged skin barriers, variable pH, exposed tissue, and frequent dressing changes.

A development program should address:

1. Aqueous compatibility. Mafenide acetate is used in aqueous topical systems, but the formulation must remain physically stable during storage and use.
2. pH control. The product should avoid unnecessary acidity or alkalinity that could increase wound discomfort or alter local tolerability.
3. Low sensitization potential. Fragrance, essential oils, aggressive preservatives, and unnecessary penetration enhancers have limited commercial value for open wounds.
4. Sterility and microbial control. A nonsterile cream may be acceptable under the approved product framework, but a sterile gel, spray, or dressing may support a different regulatory and commercial positioning.
5. Exudate management. The dosage form must remain in place without creating an occlusive film that traps excessive fluid or complicates wound assessment.
6. Active uniformity. High-load topical products require control of content uniformity, sedimentation, crystallization, and dose delivery through the container.
7. Systemic exposure. Excipient-driven enhancement of skin penetration could increase systemic mafenide exposure and potential metabolic effects. Penetration enhancement should not be a default development goal.

What excipient strategies could improve Sulfamylon?

Hydrophilic hydrogel

A hydrogel could provide more uniform spreading and easier removal than a fatty or semi-occlusive cream. Candidate systems include carbomer, poloxamer, cellulose derivatives, and other wound-compatible polymers.

Commercial advantages include:

• Better visual coverage of irregular wounds
• Lower residue after dressing removal
• Easier application through a tube or pump
• Potential integration with wound dressings
• More consistent film formation

The principal risk is excessive drying or inadequate retention on heavily exudative wounds. A hydrogel also requires careful control of pH, ionic strength, viscosity, and active distribution.

Bioadhesive polymer system

A lightly bioadhesive formulation using a wound-compatible polymer could extend residence time and reduce reapplication frequency. The target is adhesion sufficient to maintain coverage without traumatic removal.

Potential excipients include modified celluloses, polyvinyl alcohol, polyvinylpyrrolidone, poloxamers, and selected natural or semisynthetic polymers. Strong mucoadhesion is not necessarily desirable on burn tissue. The commercial claim should focus on wound residence and coverage, not maximal adhesion.

Sprayable solution or foam

A spray could reduce direct contact with painful tissue and improve application to large or anatomically difficult areas. A foam could distribute the active over a broad surface with less manual spreading.

The main technical barriers are:

• Uniform dose per actuation
• Aerosol or pump compatibility
• Control of foaming agents
• Container-closure compatibility
• Preservation or sterile manufacture
• Potential inhalation or ocular exposure during application
• Demonstration of equivalent or clinically meaningful wound coverage

A nonpropellant pump spray is likely more compatible with hospital use than a pressurized aerosol. Foam offers a stronger product differentiation opportunity but has greater device and regulatory complexity.

Dressing-impregnated formulation

Mafenide acetate could be incorporated into a gauze, nonwoven, foam, hydrofiber, or polymeric wound dressing. The excipient strategy would shift from cream rheology to active loading, release kinetics, fluid handling, and dressing removal.

This approach could reduce application labor and improve dose consistency. It may also produce a combination product requiring coordinated review of the drug, device, and manufacturing process. The commercial value is highest in burn-center protocols where dressing standardization and nursing time are major cost drivers.

Low-residue cream

A refined cream could preserve the established dosage form while improving spreadability, removal, and dressing compatibility. Development variables include:

• Lower tack
• Reduced residue
• Improved cold-temperature extrusion
• Better container emptying
• Reduced phase separation
• Controlled water loss during storage
• Compatibility with gloves and dressing materials

This is the lowest-risk formulation path if the objective is an improved generic or line extension rather than a new delivery platform.

What patents protect Sulfamylon and mafenide acetate?

Sulfamylon is a legacy product. The active ingredient and the original clinical use are old, making new composition-of-matter protection unavailable. The principal intellectual-property opportunities are formulation and delivery claims.

Orange Book status

NDA 016078 is the relevant FDA application for Sulfamylon cream. Public FDA product records and the Orange Book should be used to confirm current patent and exclusivity listings. The legacy product is not generally associated with a meaningful active Orange Book patent estate. The commercial barrier is therefore more likely to arise from regulatory requirements, manufacturing know-how, hospital purchasing, and clinical familiarity than from blocking patents [3].

Patentable subject matter for a new product

A credible patent program could cover:

• Mafenide acetate hydrogel compositions
• Specific polymer and surfactant combinations
• pH-controlled topical systems
• Low-residue or non-traumatic removal formulations
• Spray or foam dosage forms
• Dressing materials containing defined mafenide loadings
• Controlled-release wound coverings
• Container-closure systems that improve dose delivery
• Manufacturing processes that prevent crystallization or phase separation
• Methods for treating large-area burns with a defined dosing device
• Combination use with debridement, negative-pressure wound therapy, or specified dressings

Broad claims to "mafenide acetate in a topical formulation" would face substantial prior-art risk. Stronger claims would require measurable technical limitations, such as particle-size control, viscosity range, release profile, adhesion performance, wound retention, or reduced application frequency.

When does Sulfamylon lose exclusivity?

Sulfamylon's primary market exclusivity has expired. The product was approved decades ago, and no meaningful new-drug exclusivity period remains. The relevant market question is therefore generic competition, not loss of an upcoming patent term.

A generic applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the same topical product. For a topical semisolid, the FDA may require comparative product characterization and, depending on the product and guidance applicable at filing, in vitro release testing or additional evidence [4].

A materially different hydrogel, foam, spray, or dressing would more likely require a 505(b)(2) application or another pathway, depending on the proposed dosage form, labeling, clinical reliance, and device component.

Are there Paragraph IV challenges to Sulfamylon?

Paragraph IV litigation is not the central risk for a legacy product without a substantial Orange Book patent estate. If an applicant identifies a listed patent, it may submit a Paragraph IV certification and trigger the statutory patent litigation framework. For Sulfamylon, the more relevant competitive event is an ANDA approval or a new 505(b)(2) product rather than a high-value patent challenge.

A proposed generic could still face regulatory hurdles involving:

• Product sameness
• Active-ingredient equivalence
• Topical performance
• Inactive-ingredient differences
• Container and closure performance
• Microbial quality
• Labeling and application instructions

What commercial opportunities exist for improved Sulfamylon products?

Hospital-focused ready-to-use product

A ready-to-use product in a larger, ergonomic container could reduce preparation and application time. The value proposition would be operational:

• Faster wound coverage
• Lower nursing labor
• Less product waste
• More consistent application
• Easier documentation of administered dose

Burn centers and trauma hospitals would be the primary customers. Formulary adoption would depend on clinical familiarity, supply reliability, and total treatment cost.

Unit-dose and procedure-pack formats

Single-use packets or procedure kits could support sterile workflows and reduce contamination risk. A kit could combine the mafenide product with compatible applicators, dressings, gloves, and measurement tools.

The excipient itself would not create the full commercial advantage. Packaging, workflow, and hospital procurement integration would matter as much as the formulation.

Pediatric and anatomically difficult applications

A low-contact spray or foam could address painful application on pediatric patients, facial burns, hands, feet, and irregular wound surfaces. Any pediatric positioning would require careful evidence because systemic absorption and tolerability can differ with treated surface area and skin condition.

Combination wound-care products

Potential commercial combinations include mafenide with:

• Advanced absorptive dressings
• Nonadherent contact layers
• Hydrogels
• Negative-pressure wound therapy interfaces
• Debridement protocols
• Other topical antimicrobials

Combination claims must avoid implying unsupported clinical superiority. The strongest development case would link the product to a measurable operational or pharmacologic advantage.

How does Sulfamylon compare with competing topical burn products?

Product class	Typical advantage	Main limitation	Mafenide opportunity
Silver sulfadiazine cream	Familiar, broad historical use	Cream handling, repeated application, evolving clinical preferences	Improve application and dressing integration
Mafenide acetate cream	Broad antimicrobial activity and burn-center familiarity	Pain, residue, reapplication burden, systemic absorption concerns	Create lower-contact, lower-residue delivery
Bacitracin or combination ointments	Simple application for selected wounds	Narrower use profile and ointment residue	Target larger-area or higher-risk burn care
Modern antimicrobial dressings	Reduced handling and longer wear time	Cost, product-specific workflow, variable drug release	Embed mafenide in standardized dressings
Hydrogel or foam systems	Coverage and application convenience	Stability, dose uniformity, device complexity	Develop a ready-to-use mafenide platform

The competitive advantage of a new mafenide product would need to be demonstrated against actual wound-care workflow, not only antimicrobial activity. Relevant endpoints could include application time, dressing-change time, product waste, wound coverage uniformity, pain scores, removal trauma, and hospital cost per treated day.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barriers are formulation uniformity and scalable packaging. A high-strength topical product must maintain consistent active distribution throughout filling and shelf life. Manufacturing development should evaluate:

• Mixing order and shear
• Temperature control
• Particle-size distribution
• Bulk hold time
• Filling accuracy
• Tube or pump extractables
• Preservative effectiveness where applicable
• Stability under accelerated and long-term conditions
• Microbial limits
• Compatibility with dressings and applicators

A formulation patent is more defensible when linked to a reproducible manufacturing parameter or a measurable product property. Trade-secret protection may be valuable for process controls, filling conditions, active dispersion, and packaging performance even when composition claims are narrow.

Geographic patent coverage should prioritize the United States, European Union, United Kingdom, Japan, Canada, Australia, and major burn-care markets. Patent term should be coordinated with development timing. A late-filed formulation patent may have limited commercial value unless the product creates durable hospital adoption or supports multiple geographic launches.

What FDA pathway is most appropriate?

Product concept	Likely pathway	Main regulatory issue
Same 8.5% cream with equivalent excipients	ANDA	Pharmaceutical equivalence and topical performance
Cream with materially different excipients	ANDA or 505(b)(2), depending on sameness and FDA requirements	Justification for formulation differences
Hydrogel or foam	505(b)(2) likely	New dosage-form performance and clinical bridging
Spray with delivery device	505(b)(2) likely	Dose uniformity, device performance, exposure
Drug-loaded dressing	505(b)(2) or combination-product pathway	Drug release, device function, manufacturing controls
New burn-care indication	505(b)(2) or supplemental NDA	Clinical evidence for the new use

FDA's topical product guidance and product-specific recommendations should shape the development plan. A sponsor should define the target product profile before selecting excipients because viscosity, release, adhesion, and wound retention are interdependent [4,5].

What is the investment case for Sulfamylon formulation innovation?

The opportunity is specialized rather than mass-market. Revenue exposure is concentrated in hospital burn care and institutional purchasing. A reformulated product could command a premium only if it reduces labor, improves handling, solves a coverage problem, or integrates into a dressing protocol.

The strongest commercial scenarios are:

1. A differentiated hospital product with a measurable workflow advantage.
2. A private-label or licensing product for a generic manufacturer with topical manufacturing capacity.
3. A drug-device combination supplied through burn-care distributors.
4. A dressing partnership that embeds mafenide into an established wound-care platform.
5. A lower-cost generic cream supported by reliable supply and improved packaging.

The weakest scenario is an undifferentiated cream with minor excipient changes and no evidence of better application, retention, tolerability, or cost.

Key Takeaways

• Sulfamylon contains 8.5% mafenide acetate, equivalent to 5% mafenide.
• The existing cream uses a conventional hydrophilic base with cetyl alcohol, stearyl alcohol, polysorbate 60, and water.
• The active ingredient is old, and the main commercial barrier is not composition-of-matter patent protection.
• Formulation, device, dressing, manufacturing, and method-of-use claims offer the clearest IP opportunities.
• Hydrogels, foams, pump sprays, unit-dose packs, and drug-loaded dressings have greater differentiation potential than a minor cream reformulation.
• Systemic absorption and wound tolerability limit aggressive use of penetration enhancers.
• A same-form generic may use the ANDA route; materially different delivery systems are more likely to require 505(b)(2) development.
• Hospital workflow, application time, residue, dressing compatibility, and supply reliability are central commercial endpoints.
• The strongest licensing target is a sponsor with burn-care distribution, topical manufacturing, or advanced-dressing capabilities.

FAQs

Can mafenide acetate be reformulated as a sterile hydrogel?

Yes. A sterile hydrogel is technically plausible, but it would require control of active uniformity, viscosity, microbial quality, packaging, wound compatibility, and drug release. The regulatory pathway would likely be more complex than an equivalent cream.

Does Sulfamylon have biosimilar risk?

No. Mafenide acetate is a small-molecule drug, so biosimilar regulation does not apply. Competitive risk comes from generics, 505(b)(2) products, and drug-device combinations.

Can a new excipient create market exclusivity for mafenide acetate?

An excipient alone is unlikely to create meaningful exclusivity. Protection is stronger when the excipient system produces a defined technical result, such as improved wound residence, controlled release, reduced residue, or superior dose delivery.

Is a mafenide acetate dressing likely to be a combination product?

Yes, if the dressing contributes a drug-delivery function and mafenide acetate provides the primary therapeutic action. FDA classification would depend on the product's principal mode of action and design.

What is the highest-value formulation claim for a new Sulfamylon product?

A claim linking a defined composition to a measurable clinical or operational advantage is likely to have the greatest value. Examples include extended wound residence, controlled mafenide release, reduced dressing-change frequency, uniform large-area coverage, or lower removal trauma.

References

1. U.S. Food and Drug Administration. (2023). Sulfamylon cream, 8.5% mafenide acetate: Prescribing information. NDA 016078.

2. National Library of Medicine. (n.d.). DailyMed: Sulfamylon cream, mafenide acetate. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2022). Mafenide acetate topical cream: Product-specific guidance for industry. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2022). Nonsterile semisolid dosage forms: Scale-up and postapproval changes. Center for Drug Evaluation and Research.